Treatment of cataplexy

Patent metadata

Field	Value
Publication number	US-10259780-B2
Application number	US-201715419133-A
Country	US
Kind code	B2
Filing date	Jan 30, 2017
Priority date	Mar 13, 2013
Publication date	Apr 16, 2019
Grant date	Apr 16, 2019

Abstract

The present invention relates to a method of treating cataplexy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of certain carbamate compounds.

First claim

We claim:

1. A method of treating cataplexy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I):

or a pharmaceutically acceptable salt or ester thereof;
wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and 1, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms;
x is an integer of 0 to 3, with the proviso that R may be the same or different when x is 2 or 3;
R 1 and R 2 are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, phenyl, and cycloalkyl of 3 to 7 carbon atoms; or
R 1 and R 2 can be joined to form a 5 to 7-membered unsubstituted heterocycle, wherein the heterocycle can comprise 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the oxygen atom.

2. The method of claim 1 , wherein x 0.

3. The method of claim 1 , wherein the compound of Formula I is an enantiomer of Formula I substantially free of other enantiomers or an enantiomeric mixture wherein one enantiomer of Formula I predominates.

4. The method of claim 3 , wherein the enantiomer of Formula I predominates to the extent of about 98% or greater.

5. Me method of claim 1 , wherein the cataplexy is associated with narcolepsy.

6. The method of claim 1 , wherein the cataplexy is secondary to a condition that lowers hypocretin levels in the subject.

7. The method of claim 6 , wherein the condition is selected from the group consisting of brain tumor, astrocytomas, glioblastoma, glioma, subependynoma, craniopharyngioma, arterio-venous malformations, ischemic events, multiple sclerosis, head injury, brain surgery, paraneoplastic syndromes, Neimann-Pick type C disease, and encephalitis.

8. The method of claim 1 , wherein the therapeutically effective amount of the compound of Formula 1 is from about 0.01 mg/kg/dose to about 150 mg/kg/dose.

9. The method of claim 1 , wherein the therapeutically effective amount of the compound of Formula I is from about 1 mg/day to about 7000 mg/day.

10. The method of claim 1 , wherein the compound of Formula I is administered orally.

11. The method of claim 1 , wherein the compound of Formula I is administered in the form of a capsule or tablet.

12. The method of claim 1 , wherein the compound of Formula I is administered in the form of a capsule at a dose of about 150 mg to about 300 mg without any excipients.

Assignees

• Jazz Pharmaceuticals International Iii Ltd
• Sk Biopharmaceuticals Co Ltd

Inventors

• Khayrallah Moise A
• Bream Gary
• Butts Stephen E

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P25/22

  Anxiolytics · CPC title

• A61P25/20

  Hypnotics; Sedatives · CPC title

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title

• A61P21/00

  Drugs for disorders of the muscular or neuromuscular system · CPC title